Physician profile
Rizwan A Qureshi
NPI 1659394989
$408.26
in general payments reported to CMS, 2019-2025
12 companies · $35.67 in 2025
The $35.67 reported for 2025 was less than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.19 · 2020: $91.65 · 2021: $99.69 · 2022: $111 · 2025: $35.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $85.19 | 2020-2021 | |
| Tris Pharma INC | $57.34 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $54.93 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $32.47 | 2019 | |
| Cranial Technologies, INC | $30.41 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $29.53 | 2021 | |
| Corium, LLC | $27.55 | 2022 | |
| Merck Sharp & Dohme LLC | $23.19 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.76 | 2025 | Jornay Pm |
| Cipher Pharmaceuticals US LLC | $16.91 | 2025 | Natroba, Spinosad |
| Glaxosmithkline, LLC. | $16.48 | 2022 | |
| Sanofi Pasteur INC. | $15.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.